Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

May’s top stories: Amgen’s skin cancer trial, Novartis COPD Phase III study

Amgen’s Talimogene Laherparepvec's (T-VEC) Phase III OPTiM study demonstrated durable treatment response in patients of skin cancer trial and Novartis has presented positive results from two pivotal COPD Phase III clinical trial programmes. Drugdevelopment-technology.com wraps-up key headlines from May 2015.

Go Top